Semapimod inhibits the expression of the proapoptotic and proinflammatory proteins HMGB1, Bad, Bax and COX-2
- Detailed Technology Description
- None
- *Abstract
-
The inventors have found that daily administration of semapimod decreases the protein expression of HMGB1, Bad, Bax and COX-2 in the intestines of formula-fed newborn rats exposed to hypoxia and protects against chronic intestinal injury in an animal model of necrotizing enterocolitis (NEC).Non Provisional Patent Application Filed
- *Principal Investigator
-
Name: Henri Ford
Department: Med-Surgery
Name: Ruben Zamora, Assistant Professor of SurgeryAssistan
Department: Med-Surgery
- Country/Region
- USA
For more information, please click Here

